

Innovation and
Technology Adoption
in Health Care Markets

Anupam B. Jena and
Tomas J. Philipson

The AEI Press

Publisher for the American Enterprise Institute

WASHINGTON, D.C.

Contents

LIST OF ILLUSTRATIONS	vii
FOREWORD, <i>John E. Calfee</i>	ix
ACKNOWLEDGMENTS	xv
INTRODUCTION	1
1. TECHNOLOGY ADOPTION AROUND THE WORLD	7
United States 8	
<i>Medicare</i> 9	
<i>Technology Assessment and Adoption Elsewhere</i> 12	
Europe and Elsewhere 13	
2. INNOVATION AND TECHNOLOGY ADOPTION	20
Cost-Effectiveness Criteria 20	
R&D and Dynamic Efficiency 24	
3. EMPIRICAL ANALYSIS: THE CASE OF HIV/AIDS	28
Background on HIV/AIDS and Its Treatment 29	
Valuing the Gains from Treatment: Theory 31	
Estimating Survival from HIV/AIDS 34	
<i>Estimating the Time from AIDS to Death</i> 35	
<i>Estimating the Time from HIV Infection to Death</i> 38	
Valuing the Gains from Treatment: Results 40	
Surplus Appropriation and the Gains from Future R&D 44	
Extensions to the Model 48	
<i>Income and the Value of Treatment</i> 49	
<i>Willingness to Pay versus Willingness to Accept</i> 51	

vi	INNOVATION AND TECHNOLOGY ADOPTION	
4.	COST-EFFECTIVENESS AND SURPLUS APPROPRIATION	56
	Theoretical Foundations	57
	Surplus Appropriations Implied by Cost-Effectiveness	
	Estimates in the Literature	61
	Causes of Low Surplus Appropriation:	
	Market Power?	63
	CONCLUSION	66
	APPENDIX	70
	Surplus Appropriation and Cost-Effectiveness under	
	Constant-Elasticity Demand	70
	Elasticity of Cost-Effectiveness with Respect to Supply	
	and Demand Parameters	71
	Adjustment of AIDS Survival Data from 1984–92	
	for Changes in AIDS Definition	73
	Case 1	74
	Case 2	74
	Estimating Survival from AIDS	75
	Generating Survival Conditional on HIV Infection	79
	PUBLICATION ACKNOWLEDGMENTS	81
	NOTES	83
	REFERENCES	91
	ABOUT THE AUTHORS	97

List of Illustrations

FIGURES

- 3-1 Estimated R&D Spending on HIV/AIDS by Source of Funding, 1982–2002 29
- 3-2 Estimates of New Cases of HIV Infection and AIDS and of AIDS Deaths, 1978–2003 35
- 3-3 Estimated Survival Curves for Selected Years of AIDS Diagnosis 37
- 3-4 Estimated Survival Curves for Selected Years of HIV Infection 39
- 3-5 Spending on Antiretroviral Drugs, 1987–2003 45
- 3-6 Estimated Survival Curves after HIV Infection, 1980 and 2000, and Normal Survival in 2000 47
- 4-1 Cost-Effectiveness and Producer Share of Surplus by Elasticity of Demand 60
- 4-2 Cumulative Distribution of Estimated Producer Shares 63
- A-1 Survival Curves Generated by Parameterization and by Imputation 77

TABLES

- 3-1 Antiretroviral Drug Classes 30
- 3-2 Value of Gains in HIV/AIDS Survival, Baseline Estimates, 1980–2000 41
- 3-3 Comparing the Estimated Value of Life with Estimates in the Literature, 1980–2000 43

viii INNOVATION AND TECHNOLOGY ADOPTION

- 3-4 Value of Gains in Survival when Income Varies across HIV/AIDS Patients, 1980–2000 52
- 3-5 Value of Gains in HIV/AIDS Survival as Measured by Willingness to Pay, 1980–2000 54
- 4-1 Estimated Producer Share of Social Surplus for Selected Cost-Effective Technologies 60
- A-1 Age of Normal Cohort Whose One-Year Death Rate Is Equivalent to AIDS Death Rate between Years 4 and 5 Postdiagnosis, 1984–2000 76
- A-2 Life Expectancy after a Diagnosis of AIDS, 1984–2000 78
- A-3 Average Time to Onset of AIDS and Life Expectancy after HIV Infection, 1980–2000 80